Financials data is unavailable for this security.
View more
Year on year WAVE Life Sciences Ltd 's revenues fell -4.42% from 113.31m to 108.30m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 57.51m to a larger loss of 97.01m.
| Gross margin | -- |
|---|---|
| Net profit margin | -111.64% |
| Operating margin | -124.46% |
| Return on assets | -40.66% |
|---|---|
| Return on equity | -91.62% |
| Return on investment | -71.05% |
More ▼
Cash flow in USDView more
In 2024, WAVE Life Sciences Ltd increased its cash reserves by 49.88%, or 101.79m. Cash Flow from Financing totalled 253.89m or 234.43% of revenues. In addition the company used 151.03m for operations while cash used for investing totalled 938.00k.
| Cash flow per share | -0.7223 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.8262 |
|---|---|
| Tangible book value per share | 0.8262 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.51 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
